Future agents and treatment directions in multiple myeloma

Expert Review of Hematology

Volumn 7, Issue 1, 2014, Pages 127-141

  Ocio, Enrique M ^a   Mitsiades, Constantine S ^b   Orlowski, Robert Z ^c   Anderson, Kenneth C ^b  

^a Centro de Investigacion del Cancer   (Spain)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

immunomodulatory agents; monoclonal antibodies; multiple myeloma; proteasome inhibitors; targeted agents; targeted drugs

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ARRY 520; ARRY 6244; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DARATUMUMAB; DASATINIB; DEXAMETHASONE; ELOTUZUMAB; EVEROLIMUS; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IXAZOMIB; IXAZOMIB CITRATE; LENALIDOMIDE; MELPHALAN; MYELOID DIFFERENTIATION FACTOR 88; OPROZOMIB; PERIFOSINE; POMALIDOMIDE; PR 047; PREDNISONE; PROTEASOME; PROTEIN INHIBITOR; PROTEIN KINASE B INHIBITOR; PS 241; SALINOSPORAMIDE A; SELUMETINIB; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER IMMUNOTHERAPY; HUMAN; IMMUNE SYSTEM; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UNFOLDED PROTEIN RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; BORONIC ACIDS; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEASOME INHIBITORS; PROTEIN KINASE INHIBITORS; PYRAZINES;

EID: 84893266741     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.858595     Document Type: Review

References (162)

1. Greene JA, Jones DS, Podolsky SH. Therapeutic evolution and the challenge of rational medicine. N. Engl. J. Med. 367(12), 1077-1082 (2012).
2. Kyle RA, Rajkumar SV. Multiple myeloma. N. Engl. J. Med. 351(18), 1860-1873 (2004).
3. Palumbo A, Anderson K. Multiple myeloma. N. Engl. J. Med. 364(11), 1046-1060 (2011).
4. Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5), 2516-2520 (2008).
5. Kumar SK, Lee JH, Lahuerta JJ et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia 26(5), 1153 (2012).
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000).
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
8. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol. 9(12), 1157-1165 (2008).
9. Anderson KC. New insights into therapeutic targets in myeloma. Hematology Am. Soc. Hematol. Educ. Program 2011, 184-190 (2011).
10. Dolloff NG, Talamo G. Targeted therapy of multiple myeloma. Adv. Exp. Med. Biol. 779, 197-221 (2013).
11. Hideshima T, Richardson P, Chauhan D et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61(7), 3071-3076 (2001).
12. Leblanc R, Catley LP, Hideshima T et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62(17), 4996-5000 (2002).
13. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348(26), 2609-2617 (2003).
14. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352(24), 2487-2498 (2005).
15. Richardson PG, Sonneveld P, Schuster M et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110(10), 3557-3560 (2007).
16. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59(11), 2615-2622 (1999).
17. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65, 801-847 (1996).
18. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68, 1015-1068 (1999).
19. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 268(5210), 533-539 (1995).
20. Unno M, Mizushima T, Morimoto Y et al. The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure 10(5), 609-618 (2002).
21. Rivett AJ, Hearn AR. Proteasome function in antigen presentation: immunoproteasome complexes, Peptide production, and interactions with viral proteins. Curr. Protein Pept. Sci. 5(3), 153-161 (2004).
22. Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 16(1), 76-81 (2004).
23. Mitsiades N, Mitsiades CS, Poulaki V et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl Acad. Sci. USA 99(22), 14374-14379 (2002).
24. Hideshima T, Mitsiades C, Akiyama M et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101(4), 1530-1534 (2003).
25. Hideshima T, Richardson PG, Anderson KC. Targeting proteasome inhibition in hematologic malignancies. Rev. Clin. Exp. Hematol. 7(2), 191-204 (2003).
26. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin. Cancer Res. 9(17), 6316-6325 (2003).
27. Carvalho P, Goder V, Rapoport TA. Distinct ubiquitin-ligase complexes define convergent pathways for the degradation of ER proteins. Cell 126(2), 361-373 (2006).
28. Raasi S, Wolf DH. Ubiquitin receptors and ERAD: a network of pathways to the proteasome. Semin. Cell Dev. Biol. 18(6), 780-791 (2007).
29. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 18(49), 6867-6874 (1999).
30. Cook G, Campbell JD. Immune regulation in multiple myeloma: the host-tumour conflict. Blood Rev. 13(3), 151-162 (1999).
31. Feyler S, Selby PJ, Cook G. Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM). Blood Rev. 27(3), 155-164 (2013).
32. Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 107(6), 2432-2439 (2006).
33. Barlogie B, Desikan R, Eddlemon P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of patients. Blood 98(2), 492-494 (2001).
34. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341(21), 1565-1571 (1999).
35. Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357(21), 2133-2142 (2007).
36. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357(21), 2123-2132 (2007).
37. Dimopoulos MA, Chen C, Spencer A et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23(11), 2147-2152 (2009).
38. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
39. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
40. Hallett WH, Jing W, Drobyski WR, Johnson BD. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol. Blood Marrow Transplant. 17(8), 1133-1145 (2011).
41. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99(19), 12293-12297 (2002).
42. Kearl TJ, Jing W, Gershan JA, Johnson BD. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J. Immunol. 190(11), 5620-5628 (2013).
43. Rosenblatt J, Glotzbecker B, Mills H et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/ myeloma fusion vaccine. J. Immunother. 34(5), 409-418 (2011).
44. Rosenblatt J, Vasir B, Uhl L et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 117(2), 393-402 (2011).
45. Van Valckenborgh E, Schouppe E, Movahedi K et al. Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia 26(11), 2424-2428 (2012).
46. Gorgun GT, Whitehill G, Anderson JL et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 121(15), 2975-2987 (2013).
47. Brimnes MK, Vangsted AJ, Knudsen LM et al. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR(-)/ low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand. J. Immunol. 72(6), 540-547 (2010).
48. Ramachandran IR, Martner A, Pisklakova A et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J. Immunol. 190(7), 3815-3823 (2013).
49. Sakamaki I, Kwak LW, Cha SC et al. Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. Leukemia doi:10.1038/leu.2013.177 (2013) (Epub ahead of print).
50. Mcmillin DW, Delmore J, Negri JM et al. Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function. Blood 119(15), e131-e138 (2012).
51. Chapman MA, Lawrence MS, Keats JJ et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471(7339), 467-472 (2011).
52. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106(1), 296-303 (2005).
53. Niesvizky R, Lentzsch S, Badros AZ et al. A Phase I study of PD 0332991: complete CDK4/6 inhibition and tumor response in sequential combination with bortezomib and dexamethasone for relapsed and refractory multiple myeloma. ASH Annual Meeting Abstracts 116(21), 860 (2010).
54. Stewart AK, Vij R, Laubach JP et al. Phase I study of aurora kinase inhibitor mln8237 and bortezomib in relapsed or refractory multiple myeloma. ASH Annual Meeting Abstracts 120(21), 1859 (2012).
55. Mcmillin DW, Delmore J, Weisberg E et al . Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nature Med. 16(4), 483-489 (2010).
56. Dispenzieri A, Gertz MA, Lacy MQ et al. A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk. Lymphoma 47(1), 39-42 (2006).
57. Wildes TM, Procknow E, Gao F, Dipersio JF, Vij R. Dasatinib in relapsed or plateau-phase multiple myeloma. Leuk. Lymphoma 50(1), 137-140 (2009).
58. Facon T, Leleu X, Stewart AK et al. Dasatinib in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: preliminary results of a phase I study. ASH Annual Meeting Abstracts 114(22), 1876 (2009).
59. Callander NS, Markovina S, Juckett MB et al. The addition of bevacizumab (B) to lenalidomide and low dose dexamethasone does not significantly increase response in relapsed or refractory multiple myeloma (NCI#7317). ASH Annual Meeting Abstracts 114(22), 3885 (2009).
60. Lacy MQ, Alsina M, Fonseca R et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J.Clin. Oncol. 26(19), 3196-3203 (2008).
61. Moreau P, Cavallo F, Leleu X et al. Phase I study of the anti insulin-like growth factor receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia 25(5), 872-874 (2011).
62. Von Tresckow B, Boll B, Eichenauer DA et al. A Phase II clinical trial of the anti-egfr antibody cetuximab in patients with refractory or relapsed multiple myeloma: final results. ASH Annual Meeting Abstracts 118(21), 3965 (2011).
63. Ghobrial IM, Munshi NC, Harris BN et al. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am. J. Hematol. 86(7), 573-578 (2011).
64. Scheid C, Reece D, Beksac M et al. A Phase 2, Multicenter, Nonrandomized, open-label study of dovitinib (TKI258) in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. ASH Annual Meeting Abstracts 120(21), 4055 (2012).
65. Trudel S, Bergsagel PL, Singhal S et al. A Phase I study of the safety and pharmacokinetics of escalating doses of MFGR1877S, a fibroblast growth factor receptor 3 (FGFR3) antibody, in patients with relapsed or refractory t(4;14)-positive multiple myeloma. ASH Annual Meeting Abstracts 120(21), 4029 (2012).
66. Arnulf B, Ghez D, Leblond V et al. FGFR3 tyrosine kinase inhibitor AB1010 as treatment of t(4;14) multiple myeloma. Blood 110(11), 128a-Abstract 413 (2007).
67. Zhu YX, Tiedemann R, Shi CX et al. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood 117(14), 3847-3857 (2011).
68. Annunziata CM, Davis RE, Demchenko Y et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12(2), 115-130 (2007).
69. Harvey RD, Lonial S. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol. 3(6), 639-647 (2007).
70. Gera J, Lichtenstein A. The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma. Leuk. Lymphoma 52(10), 1857-1866 (2011).
71. Peterson TR, Laplante M, Thoreen CC et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137(5), 873-886 (2009).
72. Richardson P, Lonial S, Jakubowiak A et al. Multi-center phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity. Blood 110(11), 353a-Abstract 1164 (2007).
73. Richardson PG, Wolf J, Jakubowiak A et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/ refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J. Clin. Oncol. 29(32), 4243-4249 (2011).
74. Jakubowiak AJ, Richardson PG, Zimmerman T et al. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I multiple myeloma research consortium study. Br.J. Haematol. 158(4), 472-480 (2012).
75. Guenther A, Baumann P, Burger R, Klapper W, Schmidmaier R, Gramatzki M. Single-agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma: final results of a phase I study. ASCO Meeting Abstracts 28(15 Suppl.)
76. Farag SS, Zhang S, Jansak BS et al. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk. Res. 33(11), 1475-1480 (2009).
77. Ghobrial IM, Weller E, Vij R et al. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 12(3), 263-272 (2011).
78. Mahindra A, Richardson PG, Hari P et al. Updated results of a phase I study of rad001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma with pharmacodynamic and pharmacokinetic analysis. ASH Annual Meeting Abstracts 116(21), 3051 (2010).
79. Yee AJ, Mahindra AK, Richardson PG et al. Biomarker correlation with outcomes in patients with relapsed or refractory multiple myeloma on a Phase I study of everolimus in combination with lenalidomide. ASH Annual Meeting Abstracts 118(21), 3966 (2011).
80. Hofmeister CC, Yang X, Pichiorri F et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J. Clin. Oncol. 29(25), 3427-3434 (2011).
81. Alsina M, Fonseca R, Wilson EF et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103(9), 3271-3277 (2004).
82. Holkova B, Badros AZ, Geller R et al. A phase II study of the MEK 1/2 inhibitor AZD6244 (Selumetinib, ARRY-142866) in relapsed or refractory multiple myeloma. ASH Annual Meeting Abstracts 118(21)
83. Vij R, Wang M, Kaufman JL et al. An open-label, single-arm, phase 2 (PX-171- 004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 119(24), 5661-5670 (2012).
84. Siegel DS, Martin T, Wang M et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14), 2817-2825 (2012).
85. Vij R, Siegel DS, Jagannath S et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br. J. Haematol. 158(6), 739-748 (2012).
86. Wang M, Martin T, Bensinger W et al. Final results from the phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma. ASCO Meeting Abstracts 31(15 Suppl.), 8529 (2013).
87. Moreau P, Palumbo AP, Stewart AK et al. A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM). ASCO Meeting Abstracts 29(15 Suppl.), TPS225 (2011).
88. Jakubowiak AJ, Dytfeld D, Jagannath S et al. Final results of a frontline phase 1/study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM). ASH Annual Meeting Abstracts 118(21), 631 (2011).
89. Korde N, Zingone A, Kwok M et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) in newly diagnosed multiple myeloma (MM) patients. Haematologica 98(s1), Abstract 228 (2013).
90. Sonneveld P, Asselbergs E, Zweegman S et al. Carfilzomib combined with thalidomide and dexamethasone (CTD) is an highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (MM) who are transplant candidate. ASH Annual Meeting Abstracts 120(21), 333 (2012).
91. Mikhael JR, Reeder CB, Libby EN, Iii et al. Results from the phase II dose expansion of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma. ASH Annual Meeting Abstracts 120(21), 445 (2012).
92. Bringhen S, Cavallo F, Petrucci MT et al. Carfilzomib, cyclophosphamide and dexamethasone (CCD) for newly diagnosed multiple myeloma (MM) patients: initial results of a multicenter, open label Phase II study. Haematologica 98(S1), Abstract S578 (2013).
93. Touzeau C, Kolb B, Hulin C et al. Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): results of a phase (Ph) I/II trial. ASCO Meeting Abstracts 31(15 Suppl.), 8513 (2013).
94. Berdeja JG, Hart L, Lamar R, Murphy P, Morgan S, Flinn IW. Phase I/II study of panobinostat and carfilzomib in patients (pts) with relapsed or refractory multiple myeloma (MM), interim phase i safety analysis. ASH Annual Meeting Abstracts 120(21), 4048 (2012).
95. Shah JJ, Thomas SK, Weber DM et al. Phase 1/1b Study of the efficacy and safety of the combination of panobinostat + carfilzomib in patients with relapsed and/or refractory multiple myeloma. ASH Annual Meeting Abstracts 120(21), 4081 (2012).
96. Kauffman J, Zimmerman T, Jakubowiak A et al. Phase I study of the combination of carfilzomib and panobinostat for patients with relapsed and refractory myeloma: a multicenter MMRC clinical trial. Haematologica 98(S1), Abstract P771 (2013).
97. Shah JJ, Stadtmauer EA, Abonour R et al. A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/ refractory multiple myeloma. ASH Annual Meeting Abstracts 120(21), 74 (2012).
98. Shah JJ, Thomas S, Weber DM, Wang M, Orlowski R. Phase 1 study of the novel kinesin spindle protein inhibitor arry-520 + carfilzomib(Car) In patients with relapsed and/or refractory multiple Myeloma (RRMM). Haematologica 98(S1), Abstract S579 (2013).
99. Shah JJ, Weber DM, Thomas SK et al. Phase 1 Study of the novel kinesin spindle protein inhibitor ARRY-520 + carfilzomib in patients with relapsed and/or refractory multiple myeloma. ASH Annual Meeting Abstracts 120(21), 4082 (2012).
100. Jakubowiak AJ, Siegel DS, Martin T et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003- A1 study. Leukemia doi:10.1038/ leu.2013.152 (2013) (Epub ahead of print).
101. Singhal S, Siegel DS, Martin T et al. Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis. ASH Annual Meeting Abstracts 118(21), 1876 (2011).
102. Badros AZ, Vij R, Martin T et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia doi:10.1038/ leu.2013.29 (2013) (Epub ahead of print).
103. Zhou HJ, Aujay MA, Bennett MK et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J. Med. Chem. 52(9), 3028-3038 (2009).
104. Savona MR, Berdeja JG, Lee SJ et al. A Phase 1b dose-escalation study of split-dose oprozomib (ONX0912) in patients with hematologic malignancies. ASH Annual Meeting Abstracts 120(21), 203 (2012).
105. Kaufman JL, Siegel D, Vij R et al. Clinical profile of once-daily, modified-release oprozomib tablets in patients with hematologic malignancies: results of a phase 1b/2 trial. Haematologica 98(S1), Abstract P233 (2013).
106. Kumar S, Bensinger W, Zimmerman TM et al. Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/ refractory multiple myeloma (MM): Results from a phase I study after full enrollment. ASCO Meeting Abstracts 31(15 Suppl.)
107. Lonial S, Baz RC, Wang M et al. Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM). ASCO Meeting Abstracts 30(15 Suppl.)
108. San Miguel J, Hajek R, Spicka I et al. Oral MLN9708, an investigational proteasome inhibitor, in combination with melphalan and prednisone in patients with previously untreated multiple myeloma: a phase 1 study. Haematologica 97(s1), Abstract 293 (2012).
109. Kumar SK, Berdeja JG, Niesvizky R et al. A Phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). ASH Annual Meeting Abstracts 120(21), 332 (2012).
110. Richardson PG, Spencer A, Cannell P et al. Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 118(21), 302 (2011).
111. Richardson PG, Siegel D, Baz R et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 121(11), 1961-1967 (2013).
112. Lacy MQ, Hayman SR, Gertz MA et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 27(30), 5008-5014 (2009).
113. Lacy MQ, Hayman SR, Gertz MA et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 24(11), 1934-1939 (2010).
114. Lacy MQ, Kumar SK, Laplant BR et al. Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients. ASH Annual Meeting Abstracts 120(21), 201 (2012).
115. Lacy MQ, Allred JB, Gertz MA et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 118(11), 2970-2975 (2011).
116. Leleu X, Attal M, Arnulf B et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood 121(11), 1968-1975 (2013).
117. San-Miguel JF, Weisel KC, Moreau P et al. MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/ refractory multiple myeloma (RRMM). ASCO Meeting Abstracts 31(15 Suppl.)
118. Richardson PGG, Hofmeister CC, Siegel DSD et al. MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM). ASCO Meeting Abstracts 31(15 Suppl.)
119. Mark TM, Boyer A, Rossi AC et al. ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) therapy in relapsed or refractory multiple myeloma. ASH Annual Meeting Abstracts 120(21), 77 (2012).
120. Baz R, Shain KH, Alsina M et al. Oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone for relapsed and refractory myeloma: report of the dose escalation cohort. ASH Annual Meeting Abstracts 120(21), 4062 (2012).
121. Larocca A, Montefusco V, Oliva S et al. Salvage treatment with pomalidomide- cyclophosphamide-prednisone produces similar outcomes as compared to prior therapies in patients with relapsed/refractory multiple myeloma. Haematologica 98(s1), Abstract P245 (2013).
122. Hilger JD, Berenson JR, Klein LM et al. A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM). ASCO Meeting Abstracts 31 (15 Suppl.), 8598 (2013).
123. Ponisch W, Mitrou PS, Merkle K et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J. Cancer Res. Clin. Oncol. 132(4), 205-212 (2006).
124. Poenisch W, Bourgeois M, Wang S-Y et al. Bortezomib in Combination with Bendamustine and Prednisone in the Treatment of Patients with Refractory/ Relapsed Multiple Myeloma. ASH Annual Meeting Abstracts 110(11), 2723 (2007).
125. Ludwig H, Kasparu H, Linkesch W et al. Bortezomib-bendamustine- dexamethasone in patients with relapsed/refractory multiple myeloma (MM) shows marked efficacy and is well tolerated, but assessment of PNP symptoms shows significant discrepancies between patients and physicians. ASH Annual Meeting Abstracts 118(21), 2928 (2011).
126. Hrusovsky I, Heidtmann H-H. Combination therapy of bortezomib with bendamustin in elderly patients with advanced multiple myeloma. clinical observation. ASH Annual Meeting Abstracts 110(11), 4851 (2007).
127. Rodon P, Hulin C, Pegourie B et al. Bendamustine, bortezomib and dexamethasone (BVD) in elderly mm progressive after 1st line therapy (IFM 2009-01 Trial): predictive factors of defavourable outcome. Haematologica 98(S1), Abstract P231 (2013).
128. Ponisch W, Rozanski M, Goldschmidt H et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br. J. Haematol. 143(2), 191-200 (2008).
129. Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br. J. Haematol. 155(5), 632-634 (2011).
130. Grey-Davies E, Bosworth JL, Boyd KD et al. Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. Br. J. Haematol. 156(4), 552-555, author reply
131. Lentzsch S, O'sullivan A, Kennedy RC et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 119(20), 4608-4613 (2012).
132. Ponisch W, Heyn S, Beck J et al. Lenalidomide, Bendamustine and Prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. Br. J. Haematol. 162(2), 202-209 (2013).
133. Chauhan D, Ray A, Viktorsson K et al. In vitro and In vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin. Cancer Res. 19(11), 3019-3031 (2013).
134. Zojer N, Kirchbacher K, Vesely M, Hubl W, Ludwig H. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk. Lymphoma 47(6), 1103-1109 (2006).
135. Moreau P, Voillat L, Benboukher L et al. Rituximab in CD20 positive multiple myeloma. Leukemia 21(4), 835-836 (2007).
136. Zonder JA, Mohrbacher AF, Singhal S et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120(3), 552-559 (2012).
137. Lonial S, Vij R, Harousseau JL et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J. Clin. Oncol. 30(16), 1953-1959 (2012).
138. Richardson PG, Jagannath S, Moreau P et al. A Phase 2 study of elotuzumab (Elo) in combination with lenalidomide and low-dose dexamethasone (Ld) in patients (pts) with relapsed/refractory multiple myeloma (R/R MM): updated results. ASH Annual Meeting Abstracts 120(21), 202 (2012).
139. Plesner T, Lokhorst H, Gimsing P, Nahi H, Lisby S, Richardson PG. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma - data from a dose-escalation phase I/II study. ASH Annual Meeting Abstracts 120(21), 73 (2012).
140. Lokhorst HM, Plesner T, Gimsing P et al. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. ASCO Meeting Abstracts 31(15 Suppl.), 8512 (2013).
141. Galli M, Salmoiraghi S, Golay J et al. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann. Hematol. 89(2), 185-190 (2010).
142. Niesvizky R, Ely S, Mark T et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 117(2), 336-342 (2011).
143. Richardson P, Mitsiades C, Colson K et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma 49(3), 502-507 (2008).
144. Wolf JL, Siegel D, Goldschmidt H et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk. Lymphoma 53(9), 1820-1823 (2012).
145. Raje N, Hari PN, Vogl DT et al. Rocilinostat (ACY-1215), a selective HDAC6 inhibitor, alone and in combination with bortezomib in multiple myeloma: preliminary results from the first-in-humans phase I/II study. ASH Annual Meeting Abstracts 120(21), 4061 (2012).
146. Dimopoulos MA, Jagannath S, Yoon S-S et al. Vantage 088: vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial. ASH Annual Meeting Abstracts 118(21), 811 (2011).
147. Siegel DS, Dimopoulos MA, Yoon S-S et al. Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. ASH Annual Meeting Abstracts 118(21), 480 (2011).
148. Richardson PG, Alsina M, Weber D et al. PANORAMA 2: panobinostat combined with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma. ASH Annual Meeting Abstracts 120(21), 634 (2011).
149. Raje N, Mahindra A, Vogl D et al. New drug partner for combination therapy in multiple myeloma (MM): development Of ACY-1215, a selective histone deacetylase inhibitor alone and in combination with bortezomib or lenalidomide. Haematologica 98(S1), Abstract P765 (2013).
150. Shah JJ, Zonder J, Cohen A et al. ARRY-520 Shows durable responses in patients with relapsed/refractory multiple myeloma in a phase 1 dose-escalation study. ASH Annual Meeting Abstracts 118(21)
151. Shah JJ, Zonder JA, Cohen A et al. The Novel KSP Inhibitor ARRY-520 Is Active Both with and without low-dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: results from a phase 2 study. ASH Annual Meeting Abstracts 120(21), 449 (2012).
152. O'Connor OA, Stewart AK, Vallone M et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin. Cancer Res. 15(22), 7085-7091 (2009).
153. Alsina M, Trudel S, Furman RR et al. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin. Cancer Res. 18(17), 4830-4840 (2012).
154. Jagannath S, Vij R, Stewart AK et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 12(5), 310-318 (2012).
155. Siegel DS, Martin T, Wang M et al. Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 116(21), 985 (2010).
156. Schey SA, Fields P, Bartlett JB et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol. 22(16), 3269-3276 (2004).
157. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br. J. Haematol. 141(1), 41-51 (2008).
158. Richardson PG, Siegel DS, Vij R et al. Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in combination with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): phase 2 results. ASH Annual Meeting Abstracts 118(21), 634 (2011).
159. Siegel DSD, Richardson PGG, Vij R et al. Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial. ASCO Meeting Abstracts 31(15 Suppl.), 8588 (2013).
160. Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 90(9), 1287-1288 (2005).
161. Berenson JR, Yellin O, Bessudo A et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 160(3), 321-330 (2013).
162. Ponisch W, Bourgeois M, Moll B et al. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J. Cancer Res. Clin. Oncol. 139(3), 499-508 (2013).